• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sirtex Medical jumps on surging sales, profits for fiscal 2016

August 24, 2016 By drugdelivery

SirtexBy Sarah Faulkner

Shares in Sirtex Medical (ASX:SRX) closed up nearly 12% today after the Australian medical device company posted huge boosts to both the bottom and top lines.

Sydney-based Sirtex Medical makes targeted liver cancer therapies using resin microspheres called SIR-sphere Y-90.

Sirtex said profits were $40.8 million (A$53.6 million), or 70¢ (A92.2¢) per share, on sales of $177.2 million (A$232.5 million) for the fiscal year ended June 30. That represents profit growth of 32.8% compared with fiscal 2015, on sales growth of 32.0%.

“This record profit result once again highlights the continued execution of our strategies that seek to expand our global footprint, build clinician awareness and referrals, and increase reimbursement coverage for patients suffering from liver cancer,” Sirtex CEO Gilman Wong said in prepared remarks. “Our core SIR-Spheres Y-90 resin microspheres business represents a long term growth opportunity for Sirtex, given our FY16 dose sales imply we have only penetrated approximately 2% of our annual addressable market opportunity, globally.”

“The Americas region continues to perform strongly, which is directly reflected through the outstanding sales results achieved in this challenging market,” added Sirtex Americas CEO Kevin Richardson. “We continue to execute against our strategic initiatives and have made significant progress during this period in the U.S. market by continuing to increase the awareness and education about SIR-Spheres Y-90 resin microspheres therapy within the oncology community. We have also made substantial inroads in our other markets including the recent approval of SIR-Spheres Y-90 resin microspheres for the treatment of unresectable liver tumors in Canada and continued market development activities with key opinion leaders in Latin America.”

Sirtex said it expects sales to grow at a double-digit clip during fiscal 2017.

The jump confirms Sirtex’s preliminary results issued in July, when the company 1st reported the higher-than-expected sales and saw share prices climb 6.5%, the largest rise in more than 8 months.

The news pushed SRX shares up 11.97% to a $26.51 (A$34.80) close today on the Australian stock market.

Filed Under: Drug-Device Combinations, MassDevice Earnings Roundup, Oncology, Wall Street Beat Tagged With: Sirtex Medical

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS